ESTRO meets Asia 2024 - Abstract Book

S276

Interdisciplinary – Upper GI

ESTRO meets Asia 2024

[6] Morinaga, T.; Iwatsuki, M.; Yamashita, K.; Harada, K.; Kurashige, J.; Nagai, Y.; Iwagami, S.; Baba, Y.; Yoshida, N.; Baba, H., Oligometastatic recurrence as a prognostic factor after curative resection of esophageal squamous cell carcinoma. Surg Today 2021, 51 (5), 798-806. [7] Li, B.; Wang, R.; Zhang, T.; Sun, X.; Jiang, C.; Li, W.; Zou, B.; Xie, P.; Meng, X.; Sun, X.; Wang, L.; Yu, J., Development and validation of a nomogram prognostic model for esophageal cancer patients with oligometastases. Scientific reports 2020, 10 (1), 11259. [8] Chen, Y.; Cheng, X.; Song, H.; Wu, A. J.; Ku, G. Y.; Lee, P.; Slingerland, M.; Koyanagi, K.; Ke, S.; Qiu, H.; Shi, W.; Gao, Y.; Chen, J., Outcomes of concurrent chemoradiotherapy versus chemotherapy alone for esophageal squamous cell cancer patients presenting with oligometastases. Journal of Thoracic Disease 2019, 11 (4), 1536-1545. [9] Lyu, J.; Li, T.; Wang, Q.; Li, F.; Diao, P.; Liu, L.; Li, C.; Lang, J., Outcomes of concurrent chemoradiotherapy versus chemotherapy alone for stage IV esophageal squamous cell carcinoma: a retrospective controlled study. Radiat Oncol 2018, 13 (1), 233. [10] Guttmann, D. M.; Mitra, N.; Bekelman, J.; Metz, J. M.; Plastaras, J.; Feng, W.; Swisher-McClure, S., Improved Overall Survival with Aggressive Primary Tumor Radiotherapy for Patients with Metastatic Esophageal Cancer. Journal of Thoracic Oncology 2017, 12 (7), 1131-1142. [11] Depypere, L.; Lerut, T.; Moons, J.; Coosemans, W.; Decker, G.; Van Veer, H.; De Leyn, P.; Nafteux, P., Isolated local recurrence or solitary solid organ metastasis after esophagectomy for cancer is not the end of the road. Diseases of the Esophagus 2017, 30 (1), 1-8.

201

Digital Poster

A Review of CROSS Neoadjuvant Chemoradiotherapy for Esophageal Cancer in Malaysian Patients

Norhidayu Salimin

Department of Radiotherapy & Oncology, National Cancer Institute, Putrajaya, Malaysia

Purpose/Objective:

Esophageal cancer is an aggressive malignancy with fatal outcomes in the vast majority of cases. Majority of Malaysian patients presents with stage IV disease and 53.9 % cases are of squamous cell carcinoma (SCC) histology. 1 Neoadjuvant chemoradiation (CRT) followed by curative intent surgery is currently the standard of care for locally advanced esophageal cancer, with the largest supporting efficacy data from the ChemoRadiotherapy for Oesophageal cancer followed by Surgery Study (CROSS) group. 2 This is a review of locally advanced esophageal SCC treated with neoadjuvant CRT in National Cancer Institute, Malaysia; which is the national referal centre for upper gastrointestinal malignancies under the Ministry of Health.

Material/Methods:

Retrospective data of patients with esophageal SCC who received neoadjuvant CRT as per the CROSS regimen from 2019-2023 was analysed. All patients received radiotherapy with total radiation dose of 41.4 Gy in 23